Healthcare
Oracle and AstraZeneca target clinical-trial recruitment and hypertension care in Abu Dhabi
Oracle and AstraZeneca said they will explore AI-enabled clinical-trial matching and care workflows, beginning with hypertension in Abu Dhabi alongside M42.
The Abu Dhabi hypertension program is the first practical use case announced under the AstraZeneca-Oracle collaboration. The companies plan to use AI, healthcare data, and clinical-workflow capabilities to help identify patients with uncontrolled hypertension and connect eligible patients with guideline-directed care and research opportunities. M42 is participating as the healthcare partner in Abu Dhabi. The broader collaboration also covers clinical-trial matching, earlier diagnosis, safety monitoring, and real-world evidence. Its significance lies in applying AI across both care delivery and clinical research, potentially helping healthcare teams find suitable patients earlier while generating evidence within everyday workflows.
Original source: Yahoo Finance